Palbociclib study for metastatic breast cancer in Egyptian patients
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests how well the drug Palbociclib works for Egyptian patients with metastatic breast cancer. It looks at how genes may affect treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have metastatic breast cancer that is hormone-receptor-positive and HER2-negative.
- Your cancer has stopped responding or never responded to hormone therapy.
- You are able to carry out daily activities with little or no help (ECOG 0 or 1).
- You have not been treated with fulvestrant or everolimus before.
- You do not have uncontrolled brain metastases or life-threatening organ spread.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at why some patients with hormone-positive, HER2-negative metastatic breast cancer develop low white blood cells (neutropenia) when taking the drug palbociclib. It aims to find risk factors and check how well the treatment works.
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This study uses prescription records to learn about real-world use of palbociclib (a cancer medicine). You may be included if you’re an adult and have filled at least one palbociclib prescription.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.